These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 31982990)

  • 1.
    Li P; Wang X; Xu C; Liu C; Zheng C; Fulham MJ; Feng D; Wang L; Song S; Huang G
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1116-1126. PubMed ID: 31982990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
    Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra and peritumoral PET radiomics analysis to predict the pathological response in breast cancer patients receiving neoadjuvant chemotherapy.
    Aksu A; Güç ZG; Küçüker KA; Alacacıoğlu A; Turgut B
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(3):500002. PubMed ID: 38527731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of
    Chen K; Wang J; Li S; Zhou W; Xu W
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1869-1880. PubMed ID: 36808002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtype-Guided
    Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
    Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
    Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
    Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline [
    Oliveira C; Oliveira F; Constantino C; Alves C; Brito MJ; Cardoso F; Costa DC
    Eur J Nucl Med Mol Imaging; 2024 Oct; 51(12):3709-3718. PubMed ID: 38922396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiomics based on
    Ou X; Zhang J; Wang J; Pang F; Wang Y; Wei X; Ma X
    Cancer Med; 2020 Jan; 9(2):496-506. PubMed ID: 31769230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of
    Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
    Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment CT and
    Rishi A; Zhang GG; Yuan Z; Sim AJ; Song EY; Moros EG; Tomaszewski MR; Latifi K; Pimiento JM; Fontaine JP; Mehta R; Harrison LB; Hoffe SE; Frakes JM
    J Med Imaging Radiat Oncol; 2021 Feb; 65(1):102-111. PubMed ID: 33258556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparing prediction performances of
    Vincent L; Jankowski C; Arnould L; Coudert B; Rouzier R; Reyal F; Humbert O; Coutant C
    Gynecol Obstet Fertil Senol; 2020 Sep; 48(9):679-686. PubMed ID: 32205278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy.
    Antunovic L; De Sanctis R; Cozzi L; Kirienko M; Sagona A; Torrisi R; Tinterri C; Santoro A; Chiti A; Zelic R; Sollini M
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1468-1477. PubMed ID: 30915523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
    Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
    Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
    Choi EK; Yoo IR; Kim SH; Park SY; O JH; Kang BJ
    Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [
    Yang M; Li X; Cai C; Liu C; Ma M; Qu W; Zhong S; Zheng E; Zhu H; Jin F; Shi H
    Eur Radiol; 2024 Jul; 34(7):4352-4363. PubMed ID: 38127071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting EGFR mutation subtypes in lung adenocarcinoma using
    Liu Q; Sun D; Li N; Kim J; Feng D; Huang G; Wang L; Song S
    Transl Lung Cancer Res; 2020 Jun; 9(3):549-562. PubMed ID: 32676319
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Li H; Xu C; Xin B; Zheng C; Zhao Y; Hao K; Wang Q; Wahl RL; Wang X; Zhou Y
    Theranostics; 2019; 9(16):4730-4739. PubMed ID: 31367253
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular subtype classification of breast cancer using established radiomic signature models based on
    Liu J; Bian H; Zhang Y; Gao Y; Yin G; Wang Z; Li X; Ma W; Xu W
    Front Biosci (Landmark Ed); 2021 Aug; 26(9):475-484. PubMed ID: 34590460
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 40.